• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药代动力学中的非参数方法

Nonparametric Methods in Population Pharmacokinetics.

作者信息

Goutelle Sylvain, Woillard Jean-Baptiste, Neely Michael, Yamada Walter, Bourguignon Laurent

机构信息

Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France.

CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France.

出版信息

J Clin Pharmacol. 2022 Feb;62(2):142-157. doi: 10.1002/jcph.1650. Epub 2020 Oct 26.

DOI:10.1002/jcph.1650
PMID:33103785
Abstract

Population pharmacokinetic (PK) modeling is a widely used approach to analyze PK data obtained from groups of individuals, in both industry and academic research. The approach can also be used to analyze pharmacodynamic (PD) data and pooled PK/PD data. There are 2 main families of population PK methods: parametric and nonparametric. The objectives of this article are to present an overview of nonparametric methods used in population pharmacokinetic modeling and to explain their specific characteristics to inform scientists and clinicians about their potential value for data analysis, simulation, dosage design, and therapeutic drug monitoring (TDM). Nonparametric methods have several interesting characteristics for population PK analysis, including computation of exact likelihoods, the ability to accommodate parameter probability distributions of any shape (eg, non-Gaussian), and to detect subpopulations and outliers. Nonparametric population methods are also highly relevant for model-based TDM and design of individualized drug dosage regimens. Several algorithms have been developed to estimate model parameter values within an individual and compute that individual's dosage to achieve target drug exposure with maximum precision and accuracy. Nonparametric modeling methods for both population and individual PK analysis are available under user-friendly packages.

摘要

群体药代动力学(PK)建模是一种广泛应用于分析从个体群体中获得的PK数据的方法,在工业和学术研究中均有应用。该方法也可用于分析药效学(PD)数据和汇总的PK/PD数据。群体PK方法主要有两大类:参数法和非参数法。本文的目的是概述群体药代动力学建模中使用的非参数方法,并解释其具体特征,以便向科学家和临床医生介绍它们在数据分析、模拟、剂量设计和治疗药物监测(TDM)方面的潜在价值。非参数方法在群体PK分析中具有几个有趣的特征,包括精确似然性的计算、适应任何形状(如非高斯)的参数概率分布的能力,以及检测亚群和异常值的能力。非参数群体方法对于基于模型的TDM和个体化药物给药方案的设计也高度相关。已经开发了几种算法来估计个体内的模型参数值,并计算该个体的剂量,以实现最大精度和准确性的目标药物暴露。用户友好的软件包提供了用于群体和个体PK分析的非参数建模方法。

相似文献

1
Nonparametric Methods in Population Pharmacokinetics.群体药代动力学中的非参数方法
J Clin Pharmacol. 2022 Feb;62(2):142-157. doi: 10.1002/jcph.1650. Epub 2020 Oct 26.
2
Parametric Approaches in Population Pharmacokinetics.群体药代动力学中的参数方法。
J Clin Pharmacol. 2022 Feb;62(2):125-141. doi: 10.1002/jcph.1633. Epub 2020 Oct 26.
3
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations.群体药代动力学中的参数和非参数方法:专家对使用、优势和局限性的讨论。
J Clin Pharmacol. 2022 Feb;62(2):158-170. doi: 10.1002/jcph.1993. Epub 2021 Dec 3.
4
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
5
Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.利用常规血清监测数据对癫痫患者丙戊酸药代动力学进行非参数群体建模:对剂量的影响
J Clin Pharm Ther. 2004 Apr;29(2):105-20. doi: 10.1111/j.1365-2710.2003.00538.x.
6
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.使用 Pmetrics 进行离群值和亚群的准确检测,这是一个用于 R 的非参数和参数药物计量学建模和模拟软件包。
Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.
7
Volterra series in pharmacokinetics and pharmacodynamics.药代动力学和药效学中的沃尔泰拉级数
J Pharmacokinet Pharmacodyn. 2003 Oct;30(5):337-62. doi: 10.1023/b:jopa.0000008158.30235.59.
8
Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods.群体药代动力学/药效学建模:参数法和非参数法
Ther Drug Monit. 2000 Jun;22(3):354-65. doi: 10.1097/00007691-200006000-00019.
9
Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.使用迭代两阶段贝叶斯技术进行同步与序贯药代动力学-药效学群体分析。
Biopharm Drug Dispos. 2007 Nov;28(8):455-73. doi: 10.1002/bdd.575.
10
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.使用非参数动力学和动力学模型对药代动力学和药效学进行同时建模。
Clin Pharmacol Ther. 1986 Jul;40(1):86-93. doi: 10.1038/clpt.1986.143.

引用本文的文献

1
Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024.全球人群药代动力学模型应用研究:2000年至2024年的文献计量分析
Front Pharmacol. 2025 May 12;16:1548023. doi: 10.3389/fphar.2025.1548023. eCollection 2025.
2
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for infections.氟康唑在危重症患者中的群体药代动力学分析:参数法和非参数法及 感染的给药模拟。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099124. doi: 10.1128/aac.00991-24. Epub 2024 Sep 26.
3
Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China.
在中国健康受试者和十二指肠溃疡患者中进行的伊拉普唑群体药代动力学建模。
Front Pharmacol. 2024 Jan 10;14:1306222. doi: 10.3389/fphar.2023.1306222. eCollection 2023.
4
Time-dependent pharmacodynamics of amikacin on growth and resistance emergence.时间依赖性阿米卡星对生长和耐药性出现的药效动力学
Microbiol Spectr. 2024 Feb 6;12(2):e0322223. doi: 10.1128/spectrum.03222-23. Epub 2024 Jan 18.
5
Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.系统性红斑狼疮患儿霉酚酸的有限采样策略及群体药代动力学模型:采用SAEM算法的双伽马吸收模型的应用
Eur J Clin Pharmacol. 2024 Jan;80(1):83-92. doi: 10.1007/s00228-023-03587-0. Epub 2023 Oct 28.
6
Bridging the Worlds of Pharmacometrics and Machine Learning.桥接药物计量学和机器学习的世界。
Clin Pharmacokinet. 2023 Nov;62(11):1551-1565. doi: 10.1007/s40262-023-01310-x. Epub 2023 Oct 6.
7
Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.造血细胞移植中静脉用白消安的群体药代动力学模型:系统评价和比较模拟。
Clin Pharmacokinet. 2023 Jul;62(7):955-968. doi: 10.1007/s40262-023-01275-x. Epub 2023 Jul 6.
8
Optimizing Vancomycin Therapy in Critically Ill Children: A Population Pharmacokinetics Study to Inform Vancomycin Area under the Curve Estimation Using Novel Biomarkers.优化危重症儿童的万古霉素治疗:一项群体药代动力学研究,以利用新型生物标志物指导万古霉素曲线下面积估计
Pharmaceutics. 2023 Apr 25;15(5):1336. doi: 10.3390/pharmaceutics15051336.
9
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients.更昔洛韦群体药代动力学和药效学分析在优化肾移植受者巨细胞病毒感染的 preemptive 治疗中的应用。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0166522. doi: 10.1128/aac.01665-22. Epub 2023 Feb 23.
10
Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach.开发预测性给药列线图以实现重症患者阿米卡星初始剂量的药代动力学/药效学目标:一种非参数方法。
Antibiotics (Basel). 2023 Jan 9;12(1):123. doi: 10.3390/antibiotics12010123.